changing your setting. We'll assume that you are happy to receive all cookies on the BTG website.
USA, 15 June 2018
The one-year results of the ACCESS PTS trial have shown that EKOS therapy (BTG) statistically improves post-thrombotic syndrome scores and sequelae as well as quality of life outcomes. Presenting the data at the Charing Cross Symposium (24–27 April, London, UK) Mark Garcia (Wilmington, USA) said that these results mean that “hope is here for post-thrombotic syndrome patients who have failed standard of care therapy”.
Read More >
Select CONTINUE to proceed to the BTG website or LEAVE to learn more at BSC.com